請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84872完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李文宗(Wen-Chung Lee) | |
| dc.contributor.author | Fan-Tsui Meng | en |
| dc.contributor.author | 孟繁璀 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:30:08Z | - |
| dc.date.copyright | 2022-10-05 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-08-29 | |
| dc.identifier.citation | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5−a population-based study. Lancet Oncol. 2014;15(1):23-34. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9):djx030. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, E Silva GA, Chen W, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working Group. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. Cancer.Net, Lung Cancer - Non-Small Cell: Statistics. available at https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. accessed date: June 2022. Scagliotti G. Improving survival in lung cancer: commitment of The Lung Ambition Alliance. Am J Manag Care. 2019;25(12 Spec No.):SP387-SP389. Peng YT, Meng FT, Su SY, Chiang CJ, Yang YW, Lee WC. A survivorship-period-cohort model for cancer survival: application to liver cancer in Taiwan, 1997–2016. Am J Epidemiol. 2021;190(9):1961-1968. Ederer F. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121. Hsu JC, Wei CF, Yang SC, Lin PC, Lee YC, Lu CY. Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open. 2020;10(5):e033427. National Health Insurance Administration, Drug Payment Regulations. available at https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979. accessed date: June 2022. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334. Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC, Yen Y. Cancers in Taiwan: practical insight from epidemiology, treatments, biomarkers, and cost. J Formos Med Assoc. 2020;119(12):1731-1741. National Health Insurance Administration, National Health Insurance Medical Service Payment Items and Payment Standards. available at https://www.nhi.gov.tw/Content_List.aspx?n=58ED9C8D8417D00B. accessed date: July 2022. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9(6):633-643. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L. Preoperative staging of lung cancer with combined PET–CT. N Engl J Med. 2009;361(1):32-39. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg. 2004;78(3):1017-1023. Lin HT, Liu FC, Wu CY, Kuo CF, Lan WC, Yu HP. Epidemiology and survival outcomes of lung cancer: a population-based study. Biomed Res Int. 2019;2019:8148156. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung cancer. 2001;31(2-3):139-148. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. Yang P. PS01. 02 national lung cancer screening program in Taiwan: the TALENT study. J Thorac Oncol. 2021;16(3):S58. Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rintoul RC, Screaton N, Wald NJ, Weller D, Whynes DK, Williamson PR, Yadegarfar G, Hansell DM. The UK lung cancer screening trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):1-146. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JWJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde SC, Prokop M, Mali WP, Hoesein FAM, van Ooijen PM, Aerts JG, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJ, Oudkerk M. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, Von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non–small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26(16):2745-2753. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Ziu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877-1883. Health Promotion Administration, Lung Cancer Early Detection Program. available at https://www.hpa.gov.tw/Pages/List.aspx?nodeid=4619. accessed date: July 2022. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84872 | - |
| dc.description.abstract | 肺癌是所有癌症中死亡率最高的。為提高肺癌存活率，國際肺癌防治聯盟-肺志氣聯盟揭櫫於2025年將肺癌5年存活率翻倍的目標。本研究使用臺灣癌症登記中心1997年7月至2018年6月的肺癌資料，利用存活年-年代-世代模型進行臺灣肺癌患者存活率之未來預測。我們發現臺灣肺癌存活率在2004診斷年之前下降，此後上升。至2025年，肺癌五年存活率將從目前的23.8%提升至38.7%，增加絕對量為14.9%，提升倍率為1.6倍。肺癌存活率2004年後上升與標靶藥物和正子斷層造影納入健保給付的時間點相吻合。低劑量電腦斷層掃描肺癌篩檢亦有助益肺癌存活率的上升。 | zh_TW |
| dc.description.abstract | Lung cancer has the highest mortality rate of all cancers. To improve the survival rate of lung cancer, the global lung cancer prevention alliance-Lung Ambition Alliance announced the goal of doubling the 5-year survival of lung cancer by 2025. We used lung cancer data from the Taiwan Cancer Registry from July 1997 to June 2018, and we predicted the future survival of lung cancer patients in Taiwan using the survivorship-period-cohort model. We found that the survival for lung cancer in Taiwan decreased before 2004 year of diagnosis and increased after that. By 2025, the 5-year survival of lung cancer will increase from 23.8% to 38.7%, an absolute increase of 14.9%, and a 1.6-fold increase. The increase in survival after 2004 coincided with when National Health Insurance paid for the targeted drugs and positron emission tomography. Lung cancer screening with low-dose computed tomography has also improved lung cancer survival. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:30:08Z (GMT). No. of bitstreams: 1 U0001-2508202223340400.pdf: 1978540 bytes, checksum: 63a92b1f2990a77de39f1789ffbfae13 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 謝辭 i 中文摘要 ii 英文摘要 iii 圖目錄 v 表目錄 vii 前言 1 方法 2 結果 4 討論 5 參考文獻 7 | |
| dc.language.iso | zh-TW | |
| dc.title | 使用存活年−年代−世代模型預測臺灣肺癌存活率至2025年 | zh_TW |
| dc.title | Predicting Lung Cancer Survival in Taiwan to 2025 Using the Survivorship-Period-Cohort model | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 廖勇柏(Yung-Po Liaw),邱昭華(Chao-Hua Chiu) | |
| dc.subject.keyword | 肺癌,存活率,存活年−年代−世代模型,預測,長期趨勢, | zh_TW |
| dc.subject.keyword | lung cancer,survival,survivorship-period-cohort model,prediction,long-term trend, | en |
| dc.relation.page | 43 | |
| dc.identifier.doi | 10.6342/NTU202202832 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-08-29 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-10-05 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2508202223340400.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.93 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。